Azimuth Capital Investment Management LLC lessened its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 6.1% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 12,396 shares of the company's stock after selling 799 shares during the quarter. Azimuth Capital Investment Management LLC's holdings in IDEXX Laboratories were worth $5,125,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds also recently made changes to their positions in IDXX. Hurley Capital LLC purchased a new position in shares of IDEXX Laboratories during the fourth quarter valued at approximately $29,000. Rialto Wealth Management LLC bought a new position in IDEXX Laboratories during the 4th quarter valued at approximately $30,000. Retirement Wealth Solutions LLC bought a new stake in IDEXX Laboratories in the fourth quarter worth $31,000. Kestra Investment Management LLC purchased a new stake in shares of IDEXX Laboratories in the fourth quarter worth $38,000. Finally, Crews Bank & Trust purchased a new position in shares of IDEXX Laboratories in the 4th quarter worth about $41,000. 87.84% of the stock is currently owned by institutional investors.
Insider Buying and Selling at IDEXX Laboratories
In related news, Director M Anne Szostak sold 3,000 shares of the stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the sale, the director now directly owns 3,061 shares of the company's stock, valued at approximately $1,426,242.34. This represents a 49.50 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP George Fennell sold 9,986 shares of IDEXX Laboratories stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the transaction, the executive vice president now directly owns 8,176 shares in the company, valued at $3,781,645.28. This represents a 54.98 % decrease in their position. The disclosure for this sale can be found here. 2.11% of the stock is owned by corporate insiders.
Analyst Upgrades and Downgrades
Several analysts recently commented on the stock. StockNews.com downgraded shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Saturday. Morgan Stanley reduced their price target on shares of IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating for the company in a research report on Wednesday, January 29th. Bank of America upped their price objective on IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a research report on Tuesday, February 4th. Stifel Nicolaus decreased their price target on IDEXX Laboratories from $450.00 to $420.00 and set a "hold" rating for the company in a research note on Monday. Finally, Piper Sandler increased their price objective on IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a research report on Monday, February 10th. Four investment analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, IDEXX Laboratories currently has a consensus rating of "Moderate Buy" and an average target price of $523.75.
Get Our Latest Stock Report on IDEXX Laboratories
IDEXX Laboratories Stock Performance
IDXX stock traded down $1.09 during trading on Tuesday, reaching $403.56. The stock had a trading volume of 359,467 shares, compared to its average volume of 617,172. The stock's 50 day moving average is $426.75 and its two-hundred day moving average is $432.85. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $548.88. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. The firm has a market cap of $32.70 billion, a PE ratio of 37.82, a PEG ratio of 3.41 and a beta of 1.50.
IDEXX Laboratories Company Profile
(
Free Report)
IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.
See Also
Before you consider IDEXX Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEXX Laboratories wasn't on the list.
While IDEXX Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
